Featured Scientific Research
Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies
Summary Series (2021/03)
This study demonstrates the reproducibility of MMDx and the lack of significant disagreement between MMDx sign outs.
Analysis of RNA Transcripts by the Molecular Microscope® Diagnostic System (MMDx®) Can Direct Management after Indication Kidney Transplant Biopsy
Summary Series (2021/03)
These two cases describe how MMDx was used to aid the management of two patients with Banff diagnoses of “borderline” and “Banff 1a TCMR.”
Revisiting the changes in the Banff Classification for antibody‐mediated rejection after kidney transplantation
Summary Series (2021/03)
This study highlights the over simplification of the diagnosis of ABMR leading to a group of patients with less good outcomes being reclassified as ‘no ABMR’. The Molecular Microscope® Diagnostic System (MMDx) may resolve these issues by providing a clear molecular interpretation of the phenotype of rejection and extent of injury.
COVID Plus: A New Diagnostic Tool to Protect Transplant Patients in the Fight Against COVID-19
White Paper (2021/02)
We must consider, therefore, that a COVID-19 infection, as well as any future COVID-19 vaccine, may trigger changes in HLA antibody profiles. This, in turn, may have a profound effect on patients’ eligibility for transplant and risk of rejection after transplant.
Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection
Summary Series (2021/02)
Tissue-level molecular analysis of heart transplant biopsies with MMDx correlates with ISHLT grade of AMR but identifies important discrepancies. MMDx is a tool for personalized, precision diagnostics and is useful for designing and testing novel therapeutic interventions.
Amplifying the Patient Voice: Key Priorities and Opportunities for Improved Transplant and Living Donor Advocacy and Outcomes During COVID-19 and Beyond
Summary Series (2021/01)
Defining patient advocacy and engagement for modern transplant and living donation care, particularly in light of the COVID-19 pandemic.
Estimating Alloantibody Levels in Highly-Sensitized Renal Allograft Candidates: Using Serial Dilutions to Demonstrate a Treatment Effect in Clinical Trials
Summary Series (2021/01)
This study used serial dilution analysis to determine the point at which cPRA could be reduced below 98%, a value previously shown to significantly increase probability of transplant.
Transplant Patient Stories
Each quarter we have transplant patient or donor families share their incredible stories with us.
Join Our Mailing List
Want to be informed about product updates and upcoming workshops?
Or, enroll via text message:
Text HLANEWS to 22828 to get started.
(•▿•)> ⇣ Scroll down to see more Tweets.
